(Q35807254)

10 August 2017

1 reference

title

The role of sulphonylureas in the management of type 2 diabetes mellitus (English)

1 reference

10 August 2017

0 references

Marc Rendell

1

1 reference

10 August 2017

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

64

1 reference

10 August 2017

issue

12

1 reference

10 August 2017

page(s)

1339-1358

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464120-00006

10 August 2017

exact match

0 references

cites work

Failure of sulfonylureas in type 2 diabetes

1 reference

12 December 2020

Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride

1 reference

12 December 2020

Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver

1 reference

12 December 2020

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

12 December 2020

Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus

1 reference

12 December 2020

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

1 reference

12 December 2020

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride

1 reference

12 December 2020

1 reference

12 December 2020

Slow elimination of glyburide in NIDDM subjects.

1 reference

12 December 2020

Combination of insulin and metformin in the treatment of type 2 diabetes

1 reference

12 December 2020

Glutamic acid decarboxylase antibodies in non-insulin-dependent diabetes patients with secondary sulfonylurea failure in Thailand.

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.

1 reference

12 December 2020

A comparison of glyburide and insulin in women with gestational diabetes mellitus

1 reference

12 December 2020

Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment

1 reference

12 December 2020

Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials

1 reference

12 December 2020

Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose.

1 reference

12 December 2020

Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

1 reference

12 December 2020

Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes

1 reference

12 December 2020

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes

1 reference

12 December 2020

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

1 reference

12 December 2020

Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes

1 reference

12 December 2020

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

1 reference

12 December 2020

Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients

1 reference

12 December 2020

Hyponatremia and sulfonylureas

1 reference

12 December 2020

Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment.

1 reference

12 December 2020

Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure

1 reference

12 December 2020

[The relatively frequent incidence of severe sulfonylurea-induced hypoglycemia in the last 25 years in Switzerland. Results of 2 surveys in Switzerland in 1969 and 1984]

1 reference

12 December 2020

Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database

1 reference

12 December 2020

Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression.

1 reference

12 December 2020

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family

1 reference

12 December 2020

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients

1 reference

12 December 2020

Acute thrombocytopenic purpura in relation to the use of drugs.

1 reference

12 December 2020

Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels

1 reference

12 December 2020

Cardiovascular effects of conventional sulfonylureas and glimepiride

1 reference

12 December 2020

Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy.

1 reference

12 December 2020

Pharmacological treatment of the obese diabetic patient

1 reference

12 December 2020

Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes

1 reference

12 December 2020

Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease

1 reference

12 December 2020

Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population

1 reference

12 December 2020

Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects.

1 reference

12 December 2020

Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

1 reference

12 December 2020

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride

1 reference

12 December 2020

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes

1 reference

12 December 2020

Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency

1 reference

12 December 2020

Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use.

1 reference

12 December 2020

Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine

1 reference

12 December 2020

Shared biochemical properties of glucotoxicity and lipotoxicity in islets decrease citrate synthase activity and increase phosphofructokinase activity

1 reference

12 December 2020

Clinical characterisation of severe hypoglycaemia--a prospective population-based study

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes

1 reference

12 December 2020

Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.

1 reference

12 December 2020

Oral antihyperglycemic agents during pregnancy and lactation: a review

1 reference

12 December 2020

Management of antidiabetic medications in overdose

1 reference

12 December 2020

Comparison of Bedtime NPH or Preprandial Regular Insulin Combined With Glibenclamide in Secondary Sulfonylurea Failure

1 reference

12 December 2020

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

1 reference

12 December 2020

Hypoglycemia in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes

1 reference

12 December 2020

Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects

1 reference

12 December 2020

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

1 reference

12 December 2020

Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations

1 reference

12 December 2020

The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.

1 reference

12 December 2020

Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management

1 reference

12 December 2020

Long-term efficacy of triple oral therapy for type 2 diabetes mellitus

1 reference

12 December 2020

Sulphonylurea dose-response relationships: relation to clinical practice

1 reference

12 December 2020

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

1 reference

12 December 2020

Carriers of an inactivating beta-cell ATP-sensitive K(+) channel mutation have normal glucose tolerance and insulin sensitivity and appropriate insulin secretion

1 reference

12 December 2020

Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects

1 reference

12 December 2020

Regulation of the absorption of dietary carbohydrate in man by two new glycosidase inhibitors

1 reference

12 December 2020

Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study

1 reference

12 December 2020

Octreotide: an antidote for sulfonylurea-induced hypoglycemia

1 reference

12 December 2020

Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure

1 reference

12 December 2020

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

12 December 2020

Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing

1 reference

12 December 2020

Comparison of efficacy, secondary failure rate, and complications of sulfonylureas

1 reference

12 December 2020

Metabolic and additional vascular effects of thiazolidinediones.

1 reference

12 December 2020

The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.

1 reference

12 December 2020

Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide

1 reference

12 December 2020

Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.

1 reference

12 December 2020

Gliclazide modified release

1 reference

12 December 2020

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

1 reference

12 December 2020

The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents.

1 reference

12 December 2020

Drug-induced hypoglycemia

1 reference

12 December 2020

Evening insulin strategy

1 reference

12 December 2020

Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action

1 reference

12 December 2020

Comparative tolerability of sulphonylureas in diabetes mellitus

1 reference

12 December 2020

Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents

1 reference

12 December 2020

Ionophoretic activity of meglitinide analogues

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration

1 reference

12 December 2020

Sulfonylureas in NIDDM.

1 reference

12 December 2020

Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin.

1 reference

12 December 2020

Mutations in the sulfonylurea receptor gene in relation to the long-term outcome of persistent hyperinsulinemic hypoglycemia of infancy

1 reference

12 December 2020

Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations

1 reference

12 December 2020

Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes

1 reference

12 December 2020

Rates of hypoglycemia in users of sulfonylureas.

1 reference

12 December 2020

The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia.

1 reference

12 December 2020

Reversible insulin resistance in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion

1 reference

12 December 2020

Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.

1 reference

12 December 2020

Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Gliclazide directly inhibits arginine-induced glucagon release

1 reference

12 December 2020

Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function

1 reference

12 December 2020

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

12 December 2020

Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

1 reference

12 December 2020

Attenuated glucose recovery from hypoglycemia in the elderly

1 reference

12 December 2020

Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus

1 reference

12 December 2020

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group

1 reference

12 December 2020

Glipizide pharmacokinetics in young and elderly volunteers

1 reference

12 December 2020

The sulfonylurea controversy: more questions from the heart

1 reference

12 December 2020

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

1 reference

12 December 2020

Diagnostic significance of antibodies to glutamic acid decarboxylase in Japanese diabetic patients with secondary oral hypoglycemic agents failure

1 reference

12 December 2020

Absolute bioavailability of glimepiride (Amaryl) after oral administration

1 reference

12 December 2020

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.

1 reference

12 December 2020

Crossover comparison of maximum dose glyburide and glipizide.

1 reference

12 December 2020

Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells

1 reference

12 December 2020

Dynamics of sulfonylurea-induced insulin release from the isolated perfused rat pancreas

1 reference

12 December 2020

Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.

1 reference

12 December 2020

Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide

1 reference

12 December 2020

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes

1 reference

12 December 2020

Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM

1 reference

12 December 2020

Pharmacokinetics of glyburide

1 reference

12 December 2020

Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas

1 reference

12 December 2020

Interaction of K(ATP) channel modulators with sulfonylurea receptor SUR2B: implication for tetramer formation and allosteric coupling of subunits

1 reference

12 December 2020

A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.

1 reference

12 December 2020

Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction

1 reference

12 December 2020

Enhancement of absorption and effect of glipizide by magnesium hydroxide

1 reference

12 December 2020

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

1 reference

12 December 2020

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs

1 reference

12 December 2020

Drug-induced hypoglycemic coma in 102 diabetic patients

1 reference

12 December 2020

Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM.

1 reference

12 December 2020

Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.

1 reference

12 December 2020

Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis.

1 reference

12 December 2020

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes

1 reference

12 December 2020

Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes.

1 reference

12 December 2020

Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels

1 reference

12 December 2020

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

12 December 2020

Influence of blood proteins on biomedical analysis. III. Pharmacokinetics and protein binding of gliclazide

1 reference

12 December 2020

Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes

1 reference

12 December 2020

Interaction of ethanol and glipizide in humans

1 reference

12 December 2020

Direct stimulation of myocardial glucose transport and glucose transporter-1 (GLUT1) and GLUT4 protein expression by the sulfonylurea glimepiride

1 reference

12 December 2020

New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime.

1 reference

12 December 2020

Effects of chronic glipizide treatment on the NIDD heart

1 reference

12 December 2020

Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal

1 reference

12 December 2020

Incidence of severe sideeffects during therapy with sulfonylureas and biguanides.

1 reference

12 December 2020

Mechanism of action of a new class of insulin secretagogues

1 reference

12 December 2020

The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro

1 reference

12 December 2020

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

12 December 2020

Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects

1 reference

12 December 2020

Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen

1 reference

12 December 2020

Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man

1 reference

12 December 2020

Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients

1 reference

12 December 2020

A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents

1 reference

12 December 2020

Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity

1 reference

12 December 2020

Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes

1 reference

12 December 2020

Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure.

1 reference

12 December 2020

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

1 reference

12 December 2020

Comparison of the effects of three sulfonylureas on in vivo insulin action

1 reference

12 December 2020

Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment

1 reference

12 December 2020

Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy

1 reference

12 December 2020

Preclinical and clinical studies on safety and tolerability of repaglinide

1 reference

12 December 2020

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

1 reference

12 December 2020

Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.

1 reference

12 December 2020

Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus

1 reference

12 December 2020

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team.

1 reference

12 December 2020

The acute effect of metformin on glucose production in the conscious dog is primarily attributable to inhibition of glycogenolysis

1 reference

12 December 2020

Mechanisms of acute and chronic hypoglycemic action of gliclazide.

1 reference

12 December 2020

Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial.

1 reference

12 December 2020

Repaglinide as monotherapy in Type 2 diabetes

1 reference

12 December 2020

Regulation of cloned ATP-sensitive K channels by adenine nucleotides and sulfonylureas: interactions between SUR1 and positively charged domains on Kir6.2.

1 reference

12 December 2020

Anti-diabetic drugs as a cause of hypoglycaemia among acute medical admissions in Hong Kong and Singapore--relationship to the prescribing patterns in diabetic patients

1 reference

12 December 2020

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

12 December 2020

Alcohol tolerance in patients with non-insulin-dependent (type 2) diabetes treated with sulphonylurea derivatives.

1 reference

12 December 2020

Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.

1 reference

12 December 2020

Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

The use of sulphonylureas in the elderly

1 reference

12 December 2020

Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep

1 reference

12 December 2020

Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control

1 reference

12 December 2020

Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers

1 reference

12 December 2020

Insulinotropic action of meglitinide analogues: modulation by an activator of ATP-sensitive K+ channels and high extracellular K+ concentrations

1 reference

12 December 2020

Combining sulfonylureas and other oral agents

1 reference

12 December 2020

Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.

1 reference

12 December 2020

ATP-sensitive K(+) channels composed of Kir6.1 and SUR2B subunits in guinea pig gastric myocytes

1 reference

12 December 2020

The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl

1 reference

12 December 2020

Insulinotropic meglitinide analogues

1 reference

12 December 2020

Glimepiride. A review of its use in the management of type 2 diabetes mellitus

1 reference

12 December 2020

Potassium channel openers require ATP to bind to and act through sulfonylurea receptors

1 reference

12 December 2020

Clinical pharmacology of glipizide

1 reference

12 December 2020

Repaglinide and related hypoglycemic benzoic acid derivatives

1 reference

12 December 2020

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

1 reference

12 December 2020

Comparative tolerability profiles of oral antidiabetic agents

1 reference

12 December 2020

Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus

1 reference

12 December 2020

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

1 reference

12 December 2020

Repaglinide pharmacokinetics in healthy young adult and elderly subjects

1 reference

12 December 2020

Selective mitochondrial KATP channel opening controls human myocardial preconditioning: too much of a good thing?

1 reference

12 December 2020

Effects of chronically elevated glucose levels on the functional properties of rat pancreatic beta-cells

1 reference

12 December 2020

A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.

1 reference

12 December 2020

Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.

1 reference

12 December 2020

Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells

1 reference

12 December 2020

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

1 reference

12 December 2020

Effect of a glucosidase inhibitor on the metabolic response of diabetic rats to a high carbohydrate diet, consisting of starch and sucrose, or glucose

1 reference

12 December 2020

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

1 reference

12 December 2020

Scope and specificity of acarbose in slowing carbohydrate absorption in man

1 reference

12 December 2020

Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

1 reference

12 December 2020

Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma.

1 reference

12 December 2020

The mechanisms underlying the unique pharmacodynamics of nateglinide

1 reference

12 December 2020

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

1 reference

12 December 2020

Pathophysiological functions of ATP-sensitive K+ channels in myocardial ischemia

1 reference

12 December 2020

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

1 reference

12 December 2020

Cardiovascular effects of oral hypoglycaemic drugs

1 reference

12 December 2020

Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion.

1 reference

12 December 2020

Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability

1 reference

12 December 2020

The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations

1 reference

12 December 2020

Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.

1 reference

12 December 2020

Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects.

1 reference

12 December 2020

Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis

1 reference

12 December 2020

The pharmacology of sulfonylureas

1 reference

12 December 2020

Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.

1 reference

12 December 2020

Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds

1 reference

12 December 2020

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

12 December 2020

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial

1 reference

12 December 2020

Repaglinide in combination therapy with metformin in Type 2 diabetes.

1 reference

12 December 2020

The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance

1 reference

12 December 2020

Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study

1 reference

12 December 2020

Molecular biology of adenosine triphosphate-sensitive potassium channels

1 reference

12 December 2020

Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.

1 reference

12 December 2020

Influence of captopril on symptomatic and hormonal responses to hypoglycaemia in humans.

1 reference

12 December 2020

Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months.

1 reference

12 December 2020

In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo?

1 reference

12 December 2020

Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting

1 reference

12 December 2020

The mode of action of thiazolidinediones

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses.

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment

1 reference

12 December 2020

Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels

1 reference

12 December 2020

The hypoglycemic sulfonamides: history and development of the problem from 1942 to 1955

1 reference

12 December 2020

Trends in use of oral hypoglycemic agents 1964-1986.

1 reference

12 December 2020

Comparison of acute and prolonged effects of glibenclamide and chlorpropamide in patients with non-insulin-dependent diabetes.

1 reference

12 December 2020

Long-term effects of glipizide on insulin secretion and blood glucose control in patients with non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects

1 reference

12 December 2020

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

1 reference

12 December 2020

Endocrine emergencies. Hypoglycaemia

1 reference

12 December 2020

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

1 reference

12 December 2020

Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers

1 reference

12 December 2020

Impairment of myocardial protection in type 2 diabetic patients

1 reference

12 December 2020

Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits

1 reference

12 December 2020

Glucotoxicity and beta-cell failure in type 2 diabetes mellitus

1 reference

12 December 2020

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

12 December 2020

Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up

1 reference

12 December 2020

Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia

1 reference

12 December 2020

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

1 reference

12 December 2020

Are hypoglycaemia and other adverse effects similar among sulphonylureas?

1 reference

12 December 2020

Glitazones: clinical effects and molecular mechanisms

1 reference

12 December 2020

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

1 reference

12 December 2020

Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues.

1 reference

12 December 2020

Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus

1 reference

12 December 2020

Thiazolidinedione-induced edema

1 reference

12 December 2020

The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide

1 reference

12 December 2020

Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells

1 reference

12 December 2020

Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease.

1 reference

12 December 2020

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

1 reference

12 December 2020

Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction

1 reference

12 December 2020

Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide

1 reference

12 December 2020

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus

1 reference

12 December 2020

Possible role of glycogen accumulation in B-cell glucotoxicity

1 reference

12 December 2020

Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment

1 reference

12 December 2020

Drug interactions of gliclazide and other sulfonylureas in protein binding in vitro and in hypoglycemic effect in rats

1 reference

12 December 2020

What is the benefit of increasing the sulfonylurea dose?

1 reference

12 December 2020

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes

1 reference

12 December 2020

Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists

1 reference

12 December 2020

Immunoreactive insulin response to a single dose of glimepiride in lean type 2 diabetic subjects.

1 reference

12 December 2020

Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.

1 reference

12 December 2020

Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin

1 reference

12 December 2020

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

1 reference

12 December 2020

Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients

1 reference

12 December 2020

Sulfonylurea effects on target tissues for insulin

1 reference

12 December 2020

Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus

1 reference

12 December 2020

Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy

1 reference

12 December 2020

Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus.

1 reference

12 December 2020

Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide

1 reference

12 December 2020

Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart

1 reference

12 December 2020

Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in Type 2 diabetes

1 reference

12 December 2020

Pharmacokinetics of repaglinide in subjects with renal impairment

1 reference

12 December 2020

Sulfonylurea receptors: ABC transporters that regulate ATP-sensitive K(+) channels

1 reference

12 December 2020

The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes

1 reference

12 December 2020

Altered Hierarchy of Protective Responses Against Severe Hypoglycemia in Normal Aging in Healthy Men

1 reference

12 December 2020

10.2165/00003495-200464120-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1005716893

0 references

1 reference